Cited by 498Cytokine Signaling Pathways and InteractionsNeuroinflammation and Neurodegeneration MechanismsTryptophan and brain disorders

The role of interleukin-6 signaling in nervous tissue

Open access
Rothaug, Michelle, Becker-Pauly, Christoph, Rose-John, Stefan·2016·Biochimica et Biophysica Acta (BBA) - Molecular Cell Research

Abstract

The cytokine interleukin-6 (IL-6) plays a critical role in the pathogenesis of inflammatory disorders and in the physiological homeostasis of neural tissue. Profound neuropathological changes, such as multiple sclerosis (MS), Parkinson's and Alzheimer's disease are associated with increased IL-6 expression in brain. Increased nocturnal concentrations of serum IL-6 are found in patients with impaired sleep whereas IL-6-deficient mice spend more time in rapid eye movement sleep associated with dreaming. IL-6 is crucial in the differentiation of oligodendrocytes, regeneration of peripheral nerves and acts as a neurotrophic factor. It exerts its cellular effects through two distinct pathways which include the anti-inflammatory pathway involving the membrane-bound IL-6 receptor (IL-6R) expressed on selective cells, including microglia, in a process known as classical signaling that is also critical for bacterial defense. In classical signaling binding of IL-6 to the membrane-bound IL-6R activates the β-receptor glycoprotein 130 (gp130) and subsequent down-stream signaling. The alternative, rather pro-inflammatory pathway, shown to mediate neurodegeneration in mice, termed trans-signaling, depends on a soluble form of the IL-6R that is capable of binding IL-6 to stimulate a response on distal cells that express gp130. A naturally occurring soluble form of gp130 (sgp130) has been identified that can specifically bind and neutralize the IL-6R/IL-6 complex. Thus, trans-signaling is blocked but classical signaling is completely unaffected. A modified, recombinant dimerized version of sgp130 (sgp130Fc) has successfully been used to block inflammatory processes in mice and may also be used in the clarification of IL-6 trans-signaling in neurological diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbamcr.2016.03.018

Cites

167 of 167 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Numerous studies have reported that intracranial IL6 and IL6 signaling using non-canonical trans-signaling modalities impact behavior.

    “Numerous studies have reported that intracranial IL6 and IL6 signaling using non-canonical trans-signaling modalities impact behavior (Rothaug et al., 2016).”

    From Origin and function of stress-induced IL-6 in murine models (2020) · cites this paper as Rothaug et al., 2016

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

3 of the 170 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Rothaug, M., Becker-Pauly, C., & Rose-John, S.
Affiliations
Christian-Albrechts-Universität zu Kiel (DE)
Venue
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Publisher
Elsevier BV
Published
2016-06
Volume
1863
Issue
6
Pages
1218-1227
ISSN
0167-4889 (ISSN-L)
OpenAlex
W2308447553
Cited by
491
References
170
Citations by year
2026: 30 · 2025: 51 · 2024: 44 · 2023: 54 · 2022: 89 · 2021: 74 · 2020: 59 · 2019: 37 · 2018: 22 · 2017: 23 · 2016: 8
FWCI
3.02
Type
journal article
Language
en
Open access
Locations
  • Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Deutsche Forschungsgemeinschaft (SFB 654)
  • Proteolysis as a Regulatory Event in Pathophysiology (SFB 877)
Topics
  • Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
interleukin-6, IL-6 signaling, neuroinflammation, multiple sclerosis, Parkinson's disease, Alzheimer's disease, sleep, REM sleep, oligodendrocyte differentiation, peripheral nerve regeneration, neurotrophic factors, soluble IL-6 receptor, gp130, trans-signaling, sgp130Fc, neurodegeneration, microglia
MeSH terms
Animals, Central Nervous System, Humans, Models, Biological, Protein Binding, Signal Transduction, Interleukin-6, Neurodegenerative Diseases, Receptors, Interleukin-6, Cytokine Receptor gp130

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review